Startseite » Young Investigator Programme » Participants YIP

Participants

Project      

Surname, first name        

Topic

Short description

Z3+C8

Baehr,
Andrea

In-vivo evaluation of T-cell activation blockade by transgenic LEA29Y

This project is designed to evaluate the impact of locally expressed transgenic LEA29Y in a porcine abdominal heart allotransplantation model. The ability of LEA29Y to protect the graft from T-cell-mediated rejection, together with its immunosuppressive effect on the recipient, will be examined.

A2

Bozoglu,
Tarik

Crispr/Cas9 Mediated Multiplex Modulation of Transgenic Pig Donor Hearts

In this project, options for ad hoc somatic modulation of donor hearts prior to xenotransplantation will be investigated. Modulation will be achieved by class II and V targeted endonucleases; delivered by nanoparticle enhanced adeno associated virus. Initially the NLRP3-inflammasome will be targeted to assess improvement in graft survival.

C1

Cohrs,
Christian

Cell sources for islet xenotransplantation of diabetes therapy

Adult human and porcine islets, as well as porcine neonatal islet cell-like clusters and ES-cell derived human beta-cell clusters, will be transplanted into the anterior chamber of the eye to assess their resilience under hyperglycemic conditions. The results will guide the selection of the most suitable source for transplantation in diabetes therapy.

B2

Fischer,
Konrad

Identification and characterisation of new xenoprotective transgenes

This project will evaluate the usefulness of candidate genes identified in existing transplantation models, and identify new candidates based on current information. The project will consider transgenes that complement the function of those in the main project and also those that act at different levels.

C3

Wolf-van Buerck,
Lelia

Screening for immunomodulatory factors to improve transplantation of multi-transgenic islets

This Young Investigator project includes an innovative in-vivo transplantation model for direct assessment of the efficacy of novel immunomodulatory transgene combinations in suppressing xenograft rejection. This screening platform provides the basis for the identification of the “ideal donor pig”.